cyrilzakka/clinical-trials huggingface dataset:
Subjective and Objective Outcome of ESS in CRSwNP

(A): Beidseitige Fronto-Spheno-Ethmoidektomie mit Erweiterung des natürlichen Zuganges zur Stirnhöhle (Draf Typ II): Unter einem Draf Typ II Zugang versteht man die Erweiterung des natürlichen Zuganges zur Stirnhöhle mit Entfernung des Bodens der Stirnhöhle zwischen der Lamina papyracea zur Augenhöhle und der mittleren Nasenmuschel.

(B): Beidseitige Fronto-Spheno-Ethmoidektomie mit maximaler Erweiterung des Zuganges zur Stirnhöhle (Draf Typ III): Unter einem Draf Typ III verste. (C) Beidseitige Spheno-Ethmoidektomie: Abtragung des Processus uncinatus, die Eröffnung der Kieferhöhle, die Eröffnung des vorderen und hinteren Siebbeinsystems und die Eröffnung der Keilbeinhöhle.

(A): Beidseitige Fronto-Spheno-Ethmoidektomie mit Erweiterung des natürlichen Zuganges zur Stirnhöhle (Draf Typ II): Unter einem Draf Typ II Zugang versteht man die Erweiterung des natürlichen Zuganges zur Stirnhöhle mit Entfernung des Bodens der Stirnhöhle zwischen der Lamina papyracea zur Augenhöhle und der mittleren Nasenmuschel.

(B): Beidseitige Fronto-Spheno-Ethmoidektomie mit maximaler Erweiterung des Zuganges zur Stirnhöhle (Draf Typ III): Unter einem Draf Typ III verste. (C) Beidseitige Spheno-Ethmoidektomie: Abtragung des Processus uncinatus, die Eröffnung der Kieferhöhle, die Eröffnung des vorderen und hinteren Siebbeinsystems und die Eröffnung der Keilbeinhöhle.

Eligibility Criteria:
Inclusion Criteria:

* Symptomatic CRSwNP patients without improvement after conservative treatment for at least 6 months Extent of disease at least Davos Polyp Score ≥ 4 points Age 18-65 years Signed consent

Exclusion Criteria:

* Previous sinunasal surgery High resolution paranasal sinus CT shows other pathology (e.g. mucocele) Incapable of judgement
The Effect of Different I:E Ratio on Gas Exchange of Patients Undergoing Gynecologic Laparoscopic Surgery With Trendelenburg Position

In patients undergoing gynecologic laparoscopic surgery with trendelenburg position, the disturbance of pulmonary gas exchange frequently occurs due to high intra-abdominal pressure. The investigators tried to evaluate the effect of various inspiratory to expiratory ratio on pulmonary gas exchange by randomized controlled trial.

In patients undergoing gynecologic laparoscopic surgery with trendelenburg position, the disturbance of pulmonary gas exchange frequently occurs due to high intra-abdominal pressure. During the laparoscopic surgery with abdominal gas insufflation, gas exchange disturbance such as CO2 retention, hypoxemia occurs in addition to high plateau airway pressure. The usual strategy against these kinds of problem is pressure-controlled ventilation. However, the gas exchange problem especially CO2 retention can not be solved in some cases. The inverse-ratio ventilation (IRV), which prolongs the inspiratory time greater than expiratory time, can be applied for adult respiratory distress syndrome. The efficacy of IRV is to improve gas-exchange status by increasing mean airway pressure and alveolar recruitment. There have been several clinical investigations which applied IRV during general anesthesia. However, there have been debates about the effect of IRV during general anesthesia. Therefore, we tried to apply the IRV for subjects undergoing laparoscopic surgery, and evaluate the effect of different I:E ratio on the pulmonary gas exchange and respiratory mechanics.

Eligibility Criteria:
Inclusion Criteria:

* patients undergoing elective gynecologic laparoscopic surgery
* the duration of pneumoperitoneum during laparoscopic surgery is more than 40 minutes

Exclusion Criteria:

* ASA (American society of anesthesiologists) classification of the subjects more than III.
* Age under 20, or more than 65 years.
* Past history of pneumothorax, COPD, asthma.
* Patients with ischemic heart disease, valvular heart disease.
Effects of Tupler's Technique on the Management of Diastasis Rectus Abdominis.

Diastasis Rectus Abdominis is the condition in which two abdominal muscles rectus abdominis separated and cause widening and thinning of Linea alba. The Tupler's Technique is Evidence Based intervention for the management of Diastasis Rectus Abdominis. The purpose of this study is to see the Effectiveness of Tupler's Technique on the Management of Diastasis Rectus Abdomins in Post-Partum Females.

Literature suggest that during pregnancy due to hormonal changes such as increased in Relaxin, estrogen and progesterone level and also increased in the size of uterus affect the aponeurosis connection of abdominal muscles and due to these changes Diastasis Rectus Abdominis is common during pregnancy especially in third trimester and in the post-partum period. we can measure diastasis rectus abdominis by different methods such as palpatory, caliper and ultrasound. The condition can be mild (two fingers gap), moderate (two to three fingers gap) and severe (more than three fingers gap). The separation of greater than 2cm is considered as Diastasis Rectus Abdominis.

In this study effectiveness of Tupler's Technique will be assessed in post-partum diastasis rectus abdominis patients. Patients will have to wear diastasis rehab splints and then perform tupler's technique exercises. The mechanism behind this is when patients wear splint the splint will keep the connective tissues in narrow position for better healing and strengthening of muscles will be done by Tuper's Technique exercises and Diastasis of Rectus Abdominis willl be treated.

Eligibility Criteria:
Inclusion Criteria:

* Primiparous and multiparous females (Vaginal delivery).
* Greater than and equal to 12 weeks post-partum
* Age limit will be18-30 years
* BMI under or equa to 29kg/m2
* Visiting with the complain of low back pain
* Diastasis of rectus abdominis at the level of umbilicus with mild, moderate and severe condition.

Exclusion Criteria:

* Other musculoskeletal disease (disc prolapse and disc bulge)
* Trauma of bowel and bladder
* Heart and respiratory conditions including sneezing and excessive coughing
* Any pelvic floor, abdominal and spinal surgery
Use Of Virtual Reality For Pain Control in Dermatological Bedside Procedures

The purpose of this research study is to explore the impact of virtual reality (VR) on pain perception during out-patient procedures such as wart removal, wound debridement, and lidocaine injections.


Eligibility Criteria:
Inclusion Criteria:

* Patients 13 years and older.
* Patient (or health care proxy when applicable) must sign an ICF.
* Patient requiring any painful dermatological bedside procedure including: wound debridement, injections and liquid nitrogen application.
* Patients willing to participate and parents able to consent.

Exclusion Criteria:

* Subjects with a diagnosis of vertigo, inner ear diseases or seizures are excluded due to the uncertainty of performance under VR conditions.
* Subjects requiring procedures on the head are also excluded to the interference of the VR headset.
Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease

This is a multi-center cross-sectional study in which the Real-time Tissue Elastography® measurements will be collected prospectively from patients with chronic hepatitis B or C virus presenting for liver biopsy.

The aim of this study is to validate the diagnostic value of Real-time Tissue Elastography® by comparison with liver histology, serum marker or FibroScan® in chronic hepatitis B or C patients.Real-time Tissue Elastography®, biopsy and serum maker are performed.

If in the hospital they can perform FibroScan®, FobroScan® also be performed. The subjects must be scheduled for liver biopsy either prior to treatment (treatment naïve) or, if previously treated, they must have been off treatment for at least six months. The time between the Real-time Tissue Elastography® , biopsy, blood sampling and FiroScan® must not exceed four weeks.

Eligibility Criteria:
Inclusion Criteria:

* Male or female and at least 20 years of age
* Chronic hepatitis B or Chronic hepatitis C
* Subject is willing to fast for 8 hours prior to each study visit

Exclusion Criteria:

* History of alcohol abuse (alcohol intake \> 20g/day)
* Evidence or history of chronic hepatitis not caused by HBV or HCV
* During 6 months before registration to this trial has completed, nucleic acid analogue preparations or interferon therapy was performed.
* Pregnant or lactating patients
* Contraindications of liver biopsy or liver resection
Study of Dasatinib (BMS-354825) in Patients With Solid Tumors

The primary objective of this study is to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) of Dasatinib (BMS-354825) in patients in Japan.


Eligibility Criteria:
Inclusion Criteria:

* Performance status (general conditions) specified by the Eastern Cooperative Oncology Group: 0-2
* Histologic or cytologic diagnosis of a solid tumor which has progressed on or following standard therapies (including relapsed disease) or for which no standard therapy exists.
* men and women, ages 20 and over
* women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 3 months after the study in such a manner that the risk of pregnancy is minimized
* Adequate hepatic function

Exclusion Criteria:

* Participants who are eligible and willing to undergo transplantation at pre- study.
* Women who are pregnant or breastfeeding with known brain metastasis or symptoms of brain metastasis
* Uncontrolled or significant bleeding disorder unrelated to a primary tumor
* Dementia or mental illness that would prohibit understanding or giving informed consent.
* Severe allergy to drugs required for appropriate supportive care of patients in this study.
* History of gastrointestinal surgery or of any digestive disorder which has the potential to inhibit absorption of the study drug.
* Pleural effusion \> Grade 1
* Patient with dysphagia
* Does not agree to blood/blood products transfusion(s)
* Donated blood over 200 mL within 4 weeks prior to the start of study therapy
* Medication that known to have a risk of causing Torsade de pointes
* Participants who are compulsorily detained for legal reasons or treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study
Double-Blind, Placebo-Controlled Trial of Eefooton in Patients With Chronic Kidney Disease

This phase II study, 24-week, double-blind, study evaluated Eefooton's safety and efficacy for patients with CKD stage 3 to 4 Not on dialysis.

The purpose of this clinical observation and research is to evaluate the eGFR changes in the renal function of patients with chronic kidney disease combination the Eefooton oral solution and commonly used chemical drugs.

Eligibility Criteria:
Inclusion Criteria:

1. Patients with chronic kidney disease who have signed the subject's consent and the glomerular filtration rate (eGFR) is less than 59ml/min/1.73m2
2. Both male and female patients aged 20-85 years old are acceptable
3. You must be able to come back at a specific time each month during the 6-month trial

Exclusion Criteria:

1. Drug abuse.
2. Heart failure (stage 3-4)
3. Mental illness (psychotic disorder, epilepsy, depression, panic disorder)
4. Patients who have undergone dialysis or are expected to have a kidney transplant in the last three months
5. The blood pressure still exceeds 150/90mmHg after using more than three antihypertensive drugs
6. Pregnancy or planning to become pregnant or breastfeeding
7. Malignant disease
8. Acute illness (hepatitis, jaundice, acute myocardial infarction) in the last 3 months
9. The patient is engaged in another research study.
10. 3 months before entering the study or having used NSAIDs, anti-rejection drugs or performing imaging agent examinations during the study
11. You have participated in other research study in the previous month
12. You have drug dependence and drinking habits
Action Observation Therapy for Lower Limb in Stroke

This study focuses on the effects of Action Observation therapy on stair walking, balance and self-efficacy in chronic stroke patients. This study will be conducted in Helping Hands Institute of Rehabilitation Sciences and Shifa Surgical Hospital Mansehra.

It is a Randomized Control Trial. Non probability convenient sampling technique will be used to assess a total number of 40 respondents. Questionnaires and consent forms will be filled by the respondents. Each patient will be screened by using a simple selection Performa relevant to inclusion and exclusion criteria.

Total 30 patients will be included in the study and then divided into two groups i.e. Action observation therapy and Convention Therapy group with 15 individuals in each. Each group will be assessed thrice i.e. pre, post and follow up surveys. Each of them will receive the convention therapy for 30 mins except for the Action Observation therapy (AOT) group, which will also receive the additional 30 minutes session of action observational training. Total 18 sessions, 3 days a week for a total of six weeks will be performed on each patient.

Fugel Meyer Assessment Scale for lower limb, Timed Up and Go test, Timed Stair Test, Step test and self-efficacy scale will be used for the assessment. Baseline assessments of both group will be done on 1st week before the application of protocol, second assessment will be done on 4th week and then final assessment will be done on 6th week of the protocol.


Eligibility Criteria:
Inclusion Criteria:

* Age between 40-60 years.
* Both male and female.
* Those who can walk more than 10 steps.
* More than 6 months since stroke onset.
* Ability to follow the study instructions-Mini mental state examination (MMSE) score ≥25
* Baseline score of the Fugel Meyer assessment scale is between20 and 60.
* Score of 3 on Modified Rankin Scale (MRS).

Exclusion Criteria:

* Patients who cannot perform the active movement of upper limb in pre-stroke condition due to musculoskeletal problems.
* Cardiopulmonary diseases which could hinder their ability to participate in the rehabilitation program in this study.
* Patients with impaired cognition.
* Orthopedic injuries
Phenoxodiol in Treating Patients With Refractory Solid Tumors

RATIONALE: Phenoxodiol may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth.

PURPOSE: Phase I trial to study the effectiveness of phenoxodiol in treating patients who have refractory solid tumors.

OBJECTIVES:

* Determine the maximum tolerated dose of phenoxodiol in patients with refractory solid tumors.
* Determine the steady-state pharmacokinetics of this drug in these patients.
* Determine the tumor response in patients treated with this drug.

OUTLINE: This is a multicenter, dose-escalation study.

Patients receive phenoxodiol IV continuously over days 1-7. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of phenoxodiol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed at 4 weeks.

PROJECTED ACCRUAL: Approximately 18-36 patients will be accrued for this study.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed solid tumor

  * Refractory to standard therapy OR
  * No standard therapy exists
* No breast cancer
* No active CNS metastases

  * Known CNS metastases must be previously treated with radiotherapy or surgery and stable for at least 4 weeks prior to study

PATIENT CHARACTERISTICS:

Age:

* 18 and over

Performance status:

* Karnofsky 60-100%

Life expectancy:

* At least 3 months

Hematopoietic:

* Platelet count greater than 100,000/mm\^3
* WBC greater than 3,000/mm\^3
* Neutrophil count greater than 1,500/mm\^3
* Hemoglobin greater than 10 g/dL (9 g/dL for women)

Hepatic:

* Bilirubin less than 1.2 mg/dL
* Transaminases no greater than 3 times upper limit of normal

Renal:

* Creatinine no greater than 1.4 mg/dL

Other:

* No active infection
* No contraindication to the insertion of a vascular access device
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* No concurrent systemic anticancer immunotherapy

Chemotherapy:

* No concurrent systemic anticancer chemotherapy

Endocrine therapy:

* No concurrent systemic anticancer hormonal therapy except luteinizing hormone-releasing hormone agonists or antagonists

Radiotherapy:

* See Disease Characteristics
* Concurrent localized radiotherapy for control of local disease complications allowed

Surgery:

* See Disease Characteristics

Other:

* Recovered from prior antineoplastic therapy
* At least 4 weeks since prior investigational agents
* No other concurrent investigational drugs
The Effects of Whole Food Intervention on Mucositis in Patients Treated for Head and Neck Cancer

This is a study to see if a Whole Food Intervention (WFI) consisting of yogurt, butter, honey, vanilla, and glutamine will lower the frequency or severity of mucositis in head and neck cancer patients undergoing standard treatment.

The proposal is a one center, open label, randomized pilot study to evaluate the safety, tolerability and compliance of a Whole Food Intervention with Standard of Care for patients with head \& neck cancer. The primary objectives are:

1. To determine whether patients will use a Whole Food Intervention 4-6 times daily, and
2. To determine whether the Whole Food Intervention will reduce the incidence of grade 2 or greater mucositis from 75% historically seen to 25% .
3. To determine whether Whole Food Intervention will reduce the incidence of treatment breaks from \>19% to \< 10% (see section 9 for comments)

This Whole Food Intervention will be taken by mouth before the start of radiation therapy, with or without chemotherapy and for the entire treatment therapy.

Mucositis-related pain and reduction of oral intake will be quantified by using validated assessment tools. Weight loss or gain, diarrhea, constipation or no change in bowel function and the use of conventional medication for radiation-induced mucositis will be recorded. Chart review and patient questionnaires will be used to establish whether a treatment break or dose reduction for radiation of chemotherapy was required due to radiation mucositis-related symptoms. Complete Chemistry Profile and Complete Blood Count will be extracted from the patients' medical oncologist's or radiation oncologist's records. The patient will continue to use standard mucositis therapies if desired as prescribed by the treating oncology physician.

The Whole Food Intervention consists of yogurt, butter, honey, vanilla, and glutamine with 3 portioning cups, equal to approximately 12 ounces, taken daily before starting radiation therapy. A questionnaire will be used to record symptoms and doses taken. The patient will continue to use standard mucositis therapies as prescribed by the treating oncology physician.

Eligibility Criteria:
Inclusion Criteria:

* Histopathologically confirmed diagnosis of head \& neck carcinoma
* Scheduled to undergo continuous daily course of radiation therapy with or without chemotherapy
* No other serious concurrent medical illness as determined by the Principle Investigator
* Absolute neutrophil count ≥ 500/mm3
* Platelet count ≥ 50,000/mm3
* No history of insulin-dependent diabetes mellitus
* No prior hypersensitivity reaction to compound components

Exclusion Criteria:

* Dislike of the available forms of the WFI
* Allergy or food intolerance relevant to the ingredients
* Lack of access to refrigerated storage for the WFI
* Inability or unwillingness to participate twice a week
* Inability to swallow
* Undergoing treatment for HIV with HIV medications
* Ongoing alcohol and/or drug abuse
Alliance With Therapeutic Entourage in Support of Young Suicidal

Regardless of age, the quality of hospital care, the confidence that the young can have in the health care team, joining parents are pivotal elements and influence followed. Family support is all the more important as 14% of young people realize a new suicidal act within three months of hospitalization for attempted suicide, and that the essential predictors appear to be the young age and quality of intra-family relationships.

The main objective of this study is to determine, through the construction of an instrument to quantify the therapeutic alliance, defined by the characteristics of the mobilization of the entourage and the mutual commitments in the care of nursing teams and the entourage, the role of early therapeutic alliance with the entourage of suicidal youth 13-40 years, whether primosuicidants or repeat offenders, on short and medium term recurrences and early mortality.


Eligibility Criteria:
Inclusion Criteria:

* Patient aged 13-40 years
* From male or female
* Supported the waning of a suicidal gesture.
* speaking and writing fluent French
* living in Upper or Lower Normandy
* signed informed consent form, and at least one of his parents after oral and written information about the study for minors.

Exclusion Criteria:

* Age \<13 years or \> 40 years
* Do not live in the Upper and Lower Normandy regions
* Detained patient
* forced hospitalization
* Patient under guardianship
* Patient with severe somatic pathology (cancer, heart failure, kidney or respiratory, central neurological disorder), scalable, or likely to be life-threatening within a period of less than one year
* Refusal to participate in the study
* Inability to respond
Formulation and Food Effect Study of AZD1386 in Healthy Volunteers

To investigate the pharmacokinetics of two oral solid formulations of AZD1386 in relation to the AZD1386 oral solution.


Eligibility Criteria:
Inclusion Criteria:

* Females must be non-fertile (Amenorrhea and no pregnancy in the last 12 months prior to enrolment or documentation of being irreversible surgically sterile).
* Healthy male volunteers with BMI between 18 and 30 kg/m2
* Clinical normal physical findings, including blood pressure, pulse rate above 45 bpm, ECG, and laboratory assessments.
* Normal QTc interval on baseline ECG, between 360-450 msec, according to the Fridericia formula.

Exclusion Criteria:

* History of severe allergy/hypersensitivity or symptoms/signs of ongoing allergy/hypersensitivity as judged by the Investigator.
* Requirement of concomitant medication during the study, excluding hormone replacement therapy (HRT) or use of drugs with enzyme inducing properties with 3 weeks of first dose
* Smoking more than 7 cigarettes per week or consumption of more than 3 portion of snuff or equivalent per day within 30 days before first administration of study drug
* A family history of short QT syndrome (SQTS) or sudden cardiac death (SCD) amongst first degree relatives and who have a QT/QTc \<360 ms
A Comparison of Visualization Between Shamrock Technique and Paramedian Transverse Scan in Lumbar Plexus Blockade

The primary objective of this study was to compare ultrasound visibility of the lumbar plexus at the intertransverse space between paramedian transverse scan and shamrock technique. Moreover obtaining a clear image of relevant structures is imperative. Thus, the secondary objective was to assess ultrasound visibility of each relevant structure and overall visibility between these two methods.

Background: Ultrasound-guided lumbar plexus block (USG LPB) is regarded as a form of advanced ultrasound-guided regional anesthesia (USGRA). One of the key challenges of USG LPB is visualization of the lumbar plexus. That are currently in use for ultrasound-guided lumbar plexus blockade - paramedian transverse scan (PMTS) and shamrock technique.

Method: Twenty-three healthy adult volunteers aged ≥ 18 years were enrolled in this prospective cohort study. Ultrasound visualization results were compared between methods.

Eligibility Criteria:
Inclusion Criteria:

* healthy volunteer, age \>/= 18

Exclusion Criteria:

* spinal deformity and history of previous back or spine surgery